Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Advanced NSCLC Biomarker Study Lacks Results in Provided Scrape

The provided medRxiv scrape contains only title and author metadata, without study results or methods sufficient for a factual rewrite.

Reconstructed trial data suggest belzutifan’s disease-free survival gain with adjuvant pembrolizumab weakens after 12 months in renal cell…

A 65-patient surgical-only cohort links CCND1 and EGFR amplification, ARID2 loss, and RYR1 mutation to worse oesophageal adenocarcinoma…

Phase 2 study will test SPGL008 plus SSGJ-706, with or without chemotherapy, in driver gene-negative advanced non-small cell…

Merck’s phase 1b/2 MK-2750 study will test safety, response, and pharmacokinetics across advanced solid tumors, including lung, pancreas,…

RADICAL will test whether Qure.ai’s qXR can speed chest X-ray prioritisation for suspected lung cancer in NHS Greater…

Tango Therapeutics reported an 82% tumor response rate with an experimental combination in advanced pancreatic cancer, signaling a…

EUROPAC outlines UK screening pathways for inherited pancreatic disease syndromes, using pedigree risk, imaging, and biospecimens to detect…

Atebimetinib, a dual-MEK inhibitor, showed broad activity in RAS- and RAF-mutant tumors by deep cyclic inhibition and blocking…

JCO abstract compares redox status in endometrioid, serous, and clear cell endometrial carcinomas, pointing to histology-specific biology.

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds